Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
Arvinas (NASDAQ: ARVN), a clinical-stage biotech company focused on targeted protein degradation, has announced it will host a webcast to discuss its Q4 and full-year 2024 financial results. The presentation will take place on Tuesday, February 11, 2025, at 8:00 a.m. ET. Management will provide both financial results and a corporate update during the event. Investors can access the webcast through the company's website under the 'Events and Presentations' section, and a replay will be available afterward.
Arvinas (NASDAQ: ARVN), una società biotech in fase clinica focalizzata sulla degradazione mirata delle proteine, ha annunciato che ospiterà un webcast per discutere i risultati finanziari del Q4 e dell'intero anno 2024. La presentazione si terrà martedì 11 febbraio 2025, alle 8:00 ET. La direzione fornirà sia i risultati finanziari che un aggiornamento aziendale durante l'evento. Gli investitori possono accedere al webcast attraverso il sito web dell'azienda nella sezione 'Eventi e Presentazioni', e una registrazione sarà disponibile successivamente.
Arvinas (NASDAQ: ARVN), una empresa biotech en etapa clínica centrada en la degradación específica de proteínas, ha anunciado que llevará a cabo un webcast para discutir sus resultados financieros del Q4 y del año completo 2024. La presentación tendrá lugar el martes 11 de febrero de 2025, a las 8:00 a.m. ET. La dirección proporcionará tanto los resultados financieros como una actualización corporativa durante el evento. Los inversores pueden acceder al webcast a través del sitio web de la empresa en la sección 'Eventos y Presentaciones', y una repetición estará disponible después.
Arvinas (NASDAQ: ARVN), 표적 단백질 분해에 초점을 맞춘 임상 단계의 바이오텍 회사가 2024년 4분기 및 연간 재무 결과를 논의하기 위한 웹캐스트를 개최한다고 발표했습니다. 발표는 2025년 2월 11일 화요일 오전 8시 ET에 진행될 예정입니다. 경영진은 이 행사에서 재무 결과와 기업 업데이트를 모두 제공할 것입니다. 투자자는 '이벤트 및 발표' 섹션의 회사 웹사이트를 통해 웹캐스트에 접근할 수 있으며, 이후 다시 보기 기능이 제공됩니다.
Arvinas (NASDAQ: ARVN), une entreprise biotechnologique en phase clinique axée sur la dégradation ciblée des protéines, a annoncé qu'elle tiendrait un webcast pour discuter de ses résultats financiers du T4 et de l'année entière 2024. La présentation aura lieu le mardi 11 février 2025, à 8h00 ET. La direction fournira à la fois les résultats financiers et une mise à jour de l'entreprise pendant l'événement. Les investisseurs peuvent accéder au webcast via le site web de l'entreprise dans la section 'Événements et Présentations', et une rediffusion sera disponible par la suite.
Arvinas (NASDAQ: ARVN), ein biomedizinisches Unternehmen in der klinischen Phase, das sich auf die gezielte Proteinabbau konzentriert, hat angekündigt, ein Webcast zu veranstalten, um die finanziellen Ergebnisse für Q4 und das gesamte Jahr 2024 zu besprechen. Die Präsentation findet am Dienstag, den 11. Februar 2025, um 8:00 Uhr ET statt. Das Management wird während der Veranstaltung sowohl die finanziellen Ergebnisse als auch ein Unternehmensupdate bereitstellen. Anleger können auf den Webcast über die Website des Unternehmens im Abschnitt 'Veranstaltungen und Präsentationen' zugreifen, und eine Wiederholung wird danach verfügbar sein.
- None.
- None.
NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year ended 2024 financial results and provide a corporate update during a live webcast on Tuesday, February 11, 2025, at 8:00 a.m. ET.
The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC® (PROteolysis Targeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
When will Arvinas (ARVN) report its Q4 2024 earnings?
How can investors access Arvinas (ARVN) Q4 2024 earnings webcast?
Will there be a replay available for Arvinas (ARVN) Q4 2024 earnings call?
What will be covered in Arvinas (ARVN) February 11, 2025 webcast?
